Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Clinical trial NCT04581629 · COMPLETED

Trial details

NCT number: NCT04581629
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Autosomal Dominant Hypocalcemia (ADH)Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Start date: 2020-09-20
Primary completion: 2023-09-07
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.